Tonix Pharmaceuticals has reported promising preclinical results for its single-dose mpox vaccine candidate, TNX-801, during the World Vaccine Congress Washington 2025. The vaccine demonstrated robust protection against mpox and rabbitpox in animal studies, with efficacy lasting up to six months.
The live-virus vaccine's ability to protect immunocompromised subjects represents a significant potential breakthrough in mpox prevention. By aligning with the World Health Organization's preferred vaccine profile, TNX-801 could provide a critical tool in managing global health emergencies related to mpox outbreaks.
The vaccine's single-dose format and extended protection duration could simplify vaccination efforts and improve global public health response strategies. This development is particularly important given the recent mpox outbreaks that have challenged healthcare systems worldwide.
Tonix's research highlights the potential for a flexible, durable vaccine that could help mitigate future infectious disease threats. The company's work underscores the importance of continued investment in vaccine research and development to address emerging global health challenges.
